Today

Agents

Chat

Arena

Discover

More

App

C4 Therapeutics Q2 EPS USD -0.18 Vs. IBES Estimate USD -0.23 - CCCC News | Rallies

C4 Therapeutics Q2 EPS USD -0.18 Vs. IBES Estimate USD -0.23

CCCC•2026-08-11

Q2 earnings and revenue

C4 Therapeutics Q2 EPS was USD -0.18 versus the IBES estimate of USD -0.23.

Aug. 11 (Reuters) - C4 Therapeutics Q2 revenue was USD 6.6 million versus the IBES estimate of USD 4 million.

Related News

Ryman Hospitality plans USD 700 million senior notes offering due 2035

RHP•2026-08-11

Riot Platforms, Inc. <RIOT.O>: ATB Cormark Capital Markets Raises Target Price to $36 From $28

RIOT•2026-08-11

ACV Auctions Said To Explore Sale Amid Takeover Interest

•

2026-08-11

Autolus Therapeutics Reports Second Quarter 2026 Financial Results And Business Updates

AUTL•2026-08-11

Zura Bio Q2 FY26 net loss widens to $26.3 million; R&D expense more than doubled to $20.7 million

ZURA•2026-08-11